First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

An abstract of the study by Massard et al defining the recommended phase II dose of LY3039478, an oral Notch signaling inhibitor and analysing pharmacokinetics (PK), pharmacodynamics (PD) (including plasma Aβ and a panel of 46 genes expressed in skin), preliminary antitumor activity, is presented. T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2016-12, Vol.69, p.S15-S15
Hauptverfasser: Massard, C, Azaro, A, Soria, J.C, Lassen, U, Le Tourneau, C, Smith, C, Ohnmacht, U, Oakley, G, Patel, B.K.R, Yuen, E.S.M, Benhadji, K.A, Rodon, J
Format: Artikel
Sprache:eng
Schlagworte:
Anticancer properties
Antitumor activity
Cancer
Genes
Hematology, Oncology and Palliative Medicine
Inhibitor drugs
Inhibitors
Metastases
Metastasis
Notch protein
Pharmacodynamics
Pharmacokinetics
Pharmacology
Signaling
Skin
Toxicity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An abstract of the study by Massard et al defining the recommended phase II dose of LY3039478, an oral Notch signaling inhibitor and analysing pharmacokinetics (PK), pharmacodynamics (PD) (including plasma Aβ and a panel of 46 genes expressed in skin), preliminary antitumor activity, is presented. The results were 103 pts were treated, 55 in dose escalation and 48 in dose confirmation. Furthermore, the recommended dose for LY3039478 monotherapy is 50 mg TIW with manageable toxicities, significant target inhibition and preliminary clinical activity.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(16)32632-6